Rahul Khara Sells 1,000 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) insider Rahul Khara sold 1,000 shares of Disc Medicine stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $69.74, for a total value of $69,740.00. Following the sale, the insider directly owned 37,793 shares in the company, valued at $2,635,683.82. This trade represents a 2.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Rahul Khara also recently made the following trade(s):

• On Friday, January 2nd, Rahul Khara sold 6,500 shares of Disc Medicine stock. The shares were sold at an average price of $78.69, for a total transaction of $511,485.00.

Disc Medicine Trading Up 4.4%

Disc Medicine stock opened at $78.20 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 23.45 and a quick ratio of 23.45. The firm’s 50 day moving average price is $84.66 and its 200-day moving average price is $73.00. Disc Medicine, Inc. has a 1 year low of $30.82 and a 1 year high of $99.50. The stock has a market cap of $2.95 billion, a P/E ratio of -14.62 and a beta of 0.87.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Thursday, November 6th. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.29). On average, equities analysts predict that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Institutional Trading of Disc Medicine

Several institutional investors have recently added to or reduced their stakes in the company. Aberdeen Group plc boosted its position in shares of Disc Medicine by 631.0% during the fourth quarter. Aberdeen Group plc now owns 234,358 shares of the company’s stock valued at $18,610,000 after buying an additional 202,297 shares during the period. Avanza Fonder AB lifted its stake in shares of Disc Medicine by 14.1% during the 4th quarter. Avanza Fonder AB now owns 1,903 shares of the company’s stock worth $151,000 after acquiring an additional 235 shares during the last quarter. SG Americas Securities LLC boosted its holdings in Disc Medicine by 161.9% during the 4th quarter. SG Americas Securities LLC now owns 21,122 shares of the company’s stock valued at $1,677,000 after acquiring an additional 13,058 shares during the period. Assenagon Asset Management S.A. grew its position in Disc Medicine by 3,329.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 357,836 shares of the company’s stock valued at $28,416,000 after acquiring an additional 347,403 shares during the last quarter. Finally, Hudson Bay Capital Management LP purchased a new stake in Disc Medicine in the third quarter worth $6,752,000. Institutional investors own 83.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on IRON. Truist Financial increased their price objective on shares of Disc Medicine from $86.00 to $114.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Morgan Stanley reiterated an “overweight” rating and issued a $120.00 price target on shares of Disc Medicine in a research report on Thursday, January 8th. Wells Fargo & Company raised their price objective on Disc Medicine from $91.00 to $109.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. TD Cowen reiterated a “buy” rating on shares of Disc Medicine in a report on Friday, December 19th. Finally, Stifel Nicolaus initiated coverage on Disc Medicine in a research report on Monday, November 3rd. They set a “buy” rating and a $125.00 target price on the stock. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Disc Medicine has an average rating of “Moderate Buy” and an average target price of $119.45.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.